explore -WSS

explore

author：entertainment 2025-10-02 00:28:28 - browse：5362

Adam's take main illustration — Molly Ferguson/STAT

Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Grail faces three suits alleging harassment, retaliation

WSS

Global childhood vaccinations edge closer to pre

Search called off for baby washed away in Pennsylvania flash flood

In the gardens at Boston Children's Hospital, families find sanctuary

STAT Report: Patient voices and perspectives

Democrats decry new health bill for going easy on private equity

What it's like to live with paralysis for one psychologist

explore

explore

entertainment

How one medical school became remarkably diverse

CDC Director Mandy Cohen on transparency, trust, and health

George Santos makes 1st court appearance after pleading not guilty to 13 counts

J&J expands global access to TB drug amid advocacy campaign

New air purifier tech could be key to improving indoor air quality

Rise in cancer among younger people worries and puzzles doctors

DIEP, the 'gold standard' of breast reconstruction, is under threat

Congress: Eradicate hepatitis C and reduce the deficit

Medicare details structure of new drug price negotiation program

Everything to know for the next Powerball drawing as jackpot hits $1 billion

leisure time

The new HIV moral panic

STAT Report: Patient voices and perspectives

New lawsuit accuses health insurer Cigna of denying claims in bulk

Why police arrested suspected Gilgo Beach killer away from his house

Congress: Eradicate hepatitis C and reduce the deficit

In the gardens at Boston Children's Hospital, families find sanctuary

entertainment

Wikipedia

entertainment

focus